Targeting TGF-β as a therapy for Alzheimer's disease
US9095126B2 · kind B2 · utility
6Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 26, 2009 |
| Grant date | Aug 4, 2015 |
| Priority date | — |
| Expiry date | Jan 24, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/008
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are compositions and methods for enhancing peripheral macrophage Aβ phagocytosis activity. The methods include inhibiting the TGF-β signaling pathway and activating the BMP signaling pathway in peripheral macrophages to promote central nervous system infiltration and enhance macrophage Aβ phagocytosis activity. Inhibition of TGF-β signaling and activation of BMP signaling in peripheral macrophages represents an advantageous anti-amyloid therapeutic approach for Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.